Targets › GAN
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Dec 2031.
Probable cytoskeletal component that directly or indirectly plays an important role in neurofilament architecture. May act as a substrate-specific adapter of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. (UniProt, Q9H2C0)
Open in Phaseline: the race on GAN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Texas Southwestern Medical Center | scAAV9/JeT-GAN Self-complementary adeno-associated virus serotype 9 (scAAV9) delivering GAN gene for gene | GAN | Phase 1 | Giant Axonal Neuropathy (GAN) | Dec 2031 |
Giant Axonal Neuropathy (GAN) (1)
other (1)
University of Texas Southwestern Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.